Lung cancer researchers often utilize the NCI-H358 cell line for its KRAS G12C mutation to test inhibitors specifically targeting this mutation, as well as explore potential combination therapy strategies. Additionally, the NCI-H358 cell line is used to study the impact of the KRAS G12C mutation on the tumor immune microenvironment and to investigate the combined therapeutic effects of immune checkpoint inhibitors with KRAS G12C inhibitors.
NCI-H358 is a human non-small cell lung cancer (NSCLC) cell line that is widely used in research related to KRAS gene mutations. The KRAS G12C mutation is relatively common in NSCLC and the NCI-H358 cell line harbors this mutation, which plays a critical role in tumor cell signaling and proliferation. Tumor cells carrying the KRAS G12C mutation may exhibit sensitivity to specific KRAS inhibitors. Because of this, NCI-H358 is invaluable for drug screening, particularly for testing KRAS inhibitors like Sotorasib (AMG 510), which targets the KRAS G12C mutation by forming a covalent bond with the cysteine residue at position 12 of the KRAS mutant protein, inhibiting its activity and affecting downstream signaling.
Cell Name: NCI-H358 (Human Non-Small Cell Lung Cancer Cell)
Catalog Number: TCHu151 (Chinese Academy of Sciences)
Growth Characteristics: Epithelial-like morphology, adherent growth
Culture Conditions: 1640 medium + 10% FBS
Culture Environment: 95% air + 5% CO₂; 37°C
NCI-H358 cells are essential in various lung cancer research applications, including:
During the actual cultivation process, the proliferation rate of NCI-H358 cells can be accelerated by optimizing the culture conditions. When the cell density is high, it is important to regularly replace the fresh culture medium or passage the cells in a timely manner. To ensure optimal growth and research outcomes, follow these best practices for NCI-H358 cell culture:
Cyagen offers comprehensive gene editing services for the NCI-H358 cell line using the Smart-CRISPR™ system, ensuring precise and efficient genetic modifications.
Gene modifications in the NCI-H358 cell line include gene knockout, point mutation, knock-in (KI), overexpression, and interference. Cyagen optimizes the culture conditions and monoclonal preparation for NCI-H358, enabling the delivery of NCI-H358 gene-edited monoclonal cells. This significantly enhances the accuracy and reliability of experiments, providing a more solid foundation for tumor immunology research.
Using the Smart-CRISPR™ cell gene editing system, Cyagen offers custom NCI-H358 knockout (KO) cell services, delivering monoclonal homozygous cells. We use an optimized transfection system to deliver RNP (ribonucleoprotein) directly into the cells, achieving a gRNA cutting efficiency of over 90%. Compared to plasmid and virus-mediated CRISPR/Cas methods, this approach significantly increases cutting efficiency and reduces off-target effects, allowing for more precise targeting of the DNA sequence.
Using the Smart-CRISPR™ cell gene editing system, we offer precise and efficient custom services for point mutation and knock-in (KI) in the NCI-H358 cell line. By transfecting the target cells with a humanized Cas protein, gRNA, and donor components through an optimized α-donor system, we achieve high-efficiency homologous recombination, with HDR (homology-directed repair) rates reaching up to 49%, enabling the delivery of monoclonal homozygous cells.
Cyagen has optimized and upgraded the transfection vector system and, leveraging years of experience in cell biology, has established a mature and stable gene overexpression system. We offer NCI-H358 stable cell pools or monoclonal cell lines that stably express exogenous genes or RNA interference elements, achieving protein expression levels more than 10 times higher.
The NCI-H358 cell line is a powerful tool in lung cancer research, particularly for studying the KRAS G12C mutation. By following best practices for cell culture and gene editing, researchers can unlock new insights into cancer biology and therapeutic strategies. Cyagen’s expertise in gene editing further enhances the research potential of NCI-H358 cells, offering precise and reliable modifications that support groundbreaking studies.
Cyagen offers a one-stop in vitro service platform for cell line/iPSC gene editing, featuring advanced cell reprogramming, genetic engineering, and cellular differentiation technologies. By integrating our one-stop phenotypic analysis platform, we can provide in vitro model development and testing services for cell lines across various disease applications. Our optimized CRISPR-Pro technology enables rapid gene editing, including the excision of large fragments, large fragment knockin, and point mutations with stable expression across various cell lines.
Contact our experts and take advantage of our optimized CRISPR-Pro gene edited cell line modeling service platform for low-cost cell line generation with rapid turnaround and stable expression.
>>Learn more about our custom cell line gene editing services